Principal Medical Writer

Attention recruitment agencies: All agency inquiries are vetted through 4DMT’s internal Talent Acquisition team. No unsolicited resumes will be accepted. The 4DMT Talent Acquisition team must expressly engage agencies on any requisition. Agencies contacting hiring managers directly will not be tolerated, and doing so may impact your ability to work with 4DMT in the future. 4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery GENERAL SUMMARY: The Principal Medical Writer will support 4D‑150, a gene therapy in late-stage development for retinal vascular diseases, including nAMD and DME, and associated BLA‑enabling activities as well as clinical stage work within the lung program. This role is responsible for the planning, development, and delivery of high‑quality clinical and regulatory documents across late‑stage development, working closely with Clinical Science, Clinical Operations, Data Science, Regulatory Affairs, Quality, and external partners. This role is expected to play a central role in BLA readiness, including oversight of the development, coordination, and execution of key BLA modules, and management of internal and external medical writing resources to ensure timely, high‑quality regulatory deliverables. The ideal candidate brings strong late clinical‑stage medical writing experience, demonstrated ability to manage complex timelines, and a deep understanding of regulatory expectations for global Phase 3 programs and BLA readiness. MAJOR DUTIES & RESPONSIBILITIES: Provide oversight for the planning, development, and execution of BLA modules, working closely with Clinical Science, Regulatory Affairs, Data Science, and Quality to ensure alignment with submission strategy and timelines. Lead and coordinate external medical writers and vendors, including selection, scope definition, timeline management, content review, and quality oversight. Ensure consistency, scientific accuracy, and regulatory alignment across BLA components and supporting clinical documents. Serve as a key point of integration between internal subject matter experts and external writing resources to support efficient document development and review cycles. Author, review, and coordinate key clinical and regulatory documents for the 4D‑150 Phase 3 program as well as for the early-phase lung program, including but not limited to protocols, protocol amendments, CSRs, IBs, DMC materials, briefing documents, and BLA‑enabling content. Lead document planning and timeline management in collaboration with cross‑functional teams to support aggressive development milestones. Ensure consistency, clarity, and scientific accuracy across clinical documents, aligning with regulatory standards and internal expectations for quality. Partner closely with Clinical Science, Biostatistics, and Clinical Operations to integrate data interpretations, safety narratives, and efficacy analyses. Manage document review cycles, address comments, and ensure timely resolution of feedback from internal stakeholders and external vendors. Maintain document version control an